Identification of a RAS-activating TMEM87A-RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer.
Alissa J CooperYoshihisa KobayashiDewey KimSarah E CliffordSasha KravetsSuzanne E DahlbergEmily S ChambersJiaqi LiDeepa RangachariTom NguyenDaniel B CostaMichael S RabinNikhil WagleLynette M ShollPasi A JänneGeoffrey R OxnardPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Sunitinib exhibited limited activity in this enriched cohort of patients with advanced NSCLC. Nonetheless, we find that RNA-seq of exceptional responders represents a potentially underutilized opportunity to identify novel oncogenic targets including oncogenic activation of RASGRF1.